These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 21409846)

  • 1. GLP-1 agonists: improving the future of patients with type 2 diabetes.
    Shubrook JH
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):2 p preceding eS2. PubMed ID: 21409846
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
    Unger J
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):eS2-9. PubMed ID: 21389296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical challenges of managing type 2 diabetes and the potential of GLP-1-based therapies.
    Zinman B
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():1-3. PubMed ID: 19878255
    [No Abstract]   [Full Text] [Related]  

  • 4. Incretins: the novel therapy of type 2 diabetes.
    Thongtang N; Sriwijitkamol A
    J Med Assoc Thai; 2008 Jun; 91(6):943-54. PubMed ID: 18697398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What's new in diabetes: incretins and C-peptide.
    Marks V
    Med Princ Pract; 2011; 20(2):101-2. PubMed ID: 21252561
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies.
    Chilton R; Wyatt J; Nandish S; Oliveros R; Lujan M
    Am J Med; 2011 Jan; 124(1 Suppl):S35-53. PubMed ID: 21194579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of glucagon-like peptide-1 on endothelial function.
    Sjöholm A
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():19-25. PubMed ID: 19878258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin based therapies for type 2 diabetes mellitus.
    Ghosh S; Collier A; Elhadd T; Malik I
    J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.
    Mannucci E; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Nov; 18(9):639-45. PubMed ID: 18849155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes.
    Sesti G
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():4-10. PubMed ID: 19878256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes.
    Edwards CM
    Br J Hosp Med (Lond); 2013 Apr; 74(4):198-201. PubMed ID: 23571389
    [No Abstract]   [Full Text] [Related]  

  • 13. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
    Pratley RE
    J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
    [No Abstract]   [Full Text] [Related]  

  • 14. [Incretin strategy in the treatment of type 2 diabetes mellitus--DPPIV].
    Perusicová J
    Vnitr Lek; 2007 Sep; 53(9):1005-9. PubMed ID: 18019673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.
    Gilbert MP; Pratley RE
    Eur J Intern Med; 2009 Jul; 20 Suppl 2():S309-18. PubMed ID: 19580950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus.
    Gilbert MP; Pratley RE
    Am J Med; 2009 Jun; 122(6 Suppl):S11-24. PubMed ID: 19464424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The physiologic role of incretin hormones: clinical applications.
    Cefalu WT
    J Am Osteopath Assoc; 2010 Mar; 110(3 Suppl 2):S8-S14. PubMed ID: 20382839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of liraglutide in a patient with type 2 diabetes and cryptogenic cirrhosis.
    D'Amico E
    Acta Biomed; 2011 Aug; 82(2):160-1. PubMed ID: 22480072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Incretin strategy in the treatment of type 2 diabetes mellitus--DPPIV--editorial].
    Rybka J
    Vnitr Lek; 2007 Sep; 53(9):934-5. PubMed ID: 18019660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.